Assuming success is required, the following results were found.

  • Read more about efforts to understand tissue damage in MS

    future damage.Developing high-powered imaging as a window to seeing how MS causes damage and as a tool for tracking the success of treatments.Past Success The MS Lesion Project was a major collaboration of investigators worldwide who sought to...

    https://mschristian.org/index.php/blog/read-more-about-efforts-to-understand-tissue-damage-in-ms
  • Managing Hep C; A New Migraine Therapy: It's PodMed Double T!

    undergo routine myotomy or to undergo POEM. They followed these individuals for 2 years. What they determined was there was success rate in 83% of thosethat had the POEM and 82% success rate in those that had the routine myotomy. Serious adverse effects...

    https://mschristian.org/index.php/blog/managing-hep-c-a-new-migraine-therapy-it-s-podmed-double-t
  • Trending News Today: FDA Accepts NDA for Topical Rosacea Treatment - Pharmacy Times

    of statistically significant improvements in inflammatory lesion count and Investigator Global Assessment treatment success. The FDA has set June 2, 2020, as the Prescription Drug User Fee Act action date, the article reported. A new study found that...

    https://mschristian.org/index.php/blog/trending-news-today-fda-accepts-nda-for-topical-rosacea-treatment-pharmacy-times
  • Sanofi and Happify Health solidify collaboration around prescription DTx designed to address mental health in people with MS

    create the biologic basis for effective drug-based therapy, medical understanding and engagement provide the keys to success with a digitized cognitive behavior therapy program. This collaboration will marry Sanofi’s patient focus and medical and...

    https://mschristian.org/index.php/blog/sanofi-and-happify-health-solidify-collaboration-around-prescription-dtx-designed-to-address-mental-health-in-people-with-ms
  • icometrix selected as one of the 150 most innovative digital health startups worldwide by CB Insights - PRNewswire

    privilege to use CB Insights' data to identify and shine a light on these companies, and we look forward to tracking their success in 2019 and beyond." "We are honored to receive this recognition by CB Insights," said Prof. Wim Van Hecke, CEO of...

    https://mschristian.org/index.php/blog/icometrix-selected-as-one-of-the-150-most-innovative-digital-health-startups-worldwide-by-cb-insights-prnewswire
  • 'We're Just Out of Shape and Weak': What We Heard This Week

    achieved high and sustained quit rates in smokers with cancer. "The fear of failure is a larger driver than the hope of success." -- David Muhlestein, PhD, JD, of the healthcare intelligence business Leavitt Partners, on how Medicare accountable care...

    https://mschristian.org/index.php/blog/we-re-just-out-of-shape-and-weak-what-we-heard-this-week
  • In tiny doses, an addiction medication moonlights as treatment for chronic pain

    and they can’t be sure that they’ll capture the reward on that promotion,” Danzon said. The drugmaker Alkermes has had huge success with its exclusive rights to the extended-release version of naltrexone, called Vivitrol. In a statement for this story,...

    https://mschristian.org/index.php/blog/in-tiny-doses-an-addiction-medication-moonlights-as-treatment-for-chronic-pain
  • A Cheap Biotech Stock Tests a Novel Treatment for Multiple Sclerosis - Barron's

    Worldwide, there are more than twice that number. Recently-approved MS treatments have thereforebeen some of the most successful biotech launches. The Ocrevus product from Roche Holding (RHHBY) hit $2.4 billion in sales in 2018, its second year on the...

    https://mschristian.org/index.php/blog/a-cheap-biotech-stock-tests-a-novel-treatment-for-multiple-sclerosis-barron-s
  • Researchers find possible causes for lacking of effective therapy for multiple sclerosis

    to date have frequently followed different objectives, which means that the definition of what constitutes therapeutic success varied from study to study. The authors state that consistent criteria should ideally be implemented in order to render the...

    https://mschristian.org/index.php/blog/researchers-find-possible-causes-for-lacking-of-effective-therapy-for-multiple-sclerosis
  • NIH trial aims to improve drug discovery for ischemic stroke

    in patients who have entered clinical trials. In the long term, we hope that this approach will increase the chance of success in pairing a brain saving treatment with the current practice of clot removal used to treat patients with potentially fatal or...

    https://mschristian.org/index.php/blog/nih-trial-aims-to-improve-drug-discovery-for-ischemic-stroke

Results 1 - 10 of 10
 
 

Follow Us on Twitter

Follow Us On Twitter - Image